Page last updated: 2024-10-29

1-methyl-3-isobutylxanthine and Carcinoma, Thymic

1-methyl-3-isobutylxanthine has been researched along with Carcinoma, Thymic in 2 studies

1-Methyl-3-isobutylxanthine: A potent cyclic nucleotide phosphodiesterase inhibitor; due to this action, the compound increases cyclic AMP and cyclic GMP in tissue and thereby activates CYCLIC NUCLEOTIDE-REGULATED PROTEIN KINASES
3-isobutyl-1-methylxanthine : An oxopurine that is xanthine which is substituted at positions 1 and 3 by methyl and isobutyl groups, respectively.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19901 (50.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gruol, DJ1
Dalton, DK1
Chedid, M1
Yoza, BK1
Brooks, JW1
Mizel, SB1

Other Studies

2 other studies available for 1-methyl-3-isobutylxanthine and Carcinoma, Thymic

ArticleYear
Phenothiazines cause a shift in the cAMP dose-response: selection of resistant variants in a murine thymoma line.
    Journal of cellular physiology, 1984, Volume: 119, Issue:1

    Topics: 1-Methyl-3-isobutylxanthine; Animals; Bucladesine; Cell Line; Drug Synergism; Female; Isoproterenol;

1984
Activation of AP-1 by IL-1 and phorbol esters in T cells. Role of protein kinase A and protein phosphatases.
    Journal of immunology (Baltimore, Md. : 1950), 1991, Aug-01, Volume: 147, Issue:3

    Topics: 1-Methyl-3-isobutylxanthine; Animals; Colforsin; Cyclic AMP; DNA-Binding Proteins; Dose-Response Rel

1991